Cerdulatinib Explained

Drug Name:	Cerdulatinib
Iupac Name:	4-(Cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
Synonyms:	PRT062070, PRT2070, DMVT-502
Routes Of Administration:	By mouth
Cas Number:	1198300-79-6
Pubchem:	44595079
Chemspiderid:	32822046
Unii:	D1LXQ45S1O
C:	20
H:	27
N:	7
O:	3
S:	1
Smiles:	CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
Stdinchi:	1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)
Stdinchikey:	BGLPECHZZQDNCD-UHFFFAOYSA-N

Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies.^[1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.^[2]

It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).^[3]

See also

• Ruxolitinib
• Fostamatinib
• Entospletinib

References

1. Liu D, Mamorska-Dyga A . Syk inhibitors in clinical development for hematological malignancies . Journal of Hematology & Oncology . 10 . 1 . 145 . July 2017 . 28754125 . 5534090 . 10.1186/s13045-017-0512-1 . free .
2. Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, Hollenbach SJ, Pandey A, Sinha U . 6 . The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer . The Journal of Pharmacology and Experimental Therapeutics . 351 . 3 . 538–48 . December 2014 . 25253883 . 10.1124/jpet.114.218164 . free .
3. Web site: Investors - News Release - Portola Pharmaceuticals, Inc.. phx.corporate-ir.net. en. September 25, 2018.